调整阴道内环境对HR-HPV感染的CINI的临床观察  

Clinical observation about vaginal environmental adjustment in cervical intraepithelial neoplasia Ⅰ infected by HR-HPV

作　　者：沙静[1] 崔健[1] 邢军利[2] 

机构地区：[1]新疆生产建设兵团医院,乌鲁木齐830002 [2]中国人民解放军第22医院,816000

出　　处：《新疆医学》2017年第3期253-255,共3页Xinjiang Medical Journal

基　　金：兵团科技局课题(2014BA042)

摘　　要：目的探讨应用阴道用乳酸菌素胶囊调整阴道内环境后对宫颈HR-HPV感染及宫颈病变逆转的可行性。方法收集于2012年6月—2014年12月在新疆生产建设兵团医院就诊的经病理学确诊为经HC-2检查感染高危型HPV,同时经宫颈液基细胞学检查及阴道镜活检确诊为宫颈内瘤变Ⅰ级(CINⅠ)[1]的门诊随访患者140例。研究中纳入治疗组71例,用阴道用乳酸菌素胶囊,应用4~6个月经周期,月经期停药;对照组69例,自然随访;比较两组的疗效。结果经治疗后4个月对照组、治疗组CINⅠ的逆转率分别为20.64%和29.58%;6个月时随访CINⅠ的逆转率分别为33.33%、47.06%;12个月时随访CINⅠ的逆转率分别为38.33%、56.92%;24个月时随访CINⅠ的逆转率分别为51.85%、70.00%,经统计学比较,12个月、24个月时治疗组CIN的逆转率明显升高,P值均<0.05,具有统计学意义。经治疗后4个月对照组、治疗组HR-HPV的转阴率分别为28.99%、40.58%;6个月时随访HR-HPV的转阴率分别为37.88%、53.03%;12个月时随访HR-HPV的转阴率分别为50.00%、67.69%;24个月时随访HR-HPV的转阴率分别为66.67%、83.33%,治疗组在各个随访时段HR-HPV的逆转率均较对照组升高,经统计学比较,P值均<0.05,具有统计学意义。结论 1.阴道乳杆菌稳定阴道内环境可促进CINⅠ的逆转率,随着干预时间的延长,其作用越明显;2.通过应用阴道乳酸杆菌调整阴道内环境可增加宫颈HR-HPV的清除率。应用阴道用乳杆菌稳定阴道内环境对合并HPV感染的CINI是一种疗效显著、安全的治疗方法,值得临床推广应用。Objective o discuss the feasibility about vagina lactobaciUus capsule being used to adjust the vaginal environment and cure cervical HR-HPV infection and cervical lesions. Methods Women aged from 25 to -55 years old who were in hospital of Xinjiang production and construction corps and were high -risk with HPV infection detected through HC -2 check from June 2012 to December 2014 were collected. All cases were diagnosed as cervical neoplasia I （CIN I ） through cervical liquid based cytology and calposcopy biopsy pathological examination. As a result, follow-up outpatients were 140 cases. And there were 71 cases who were collected in treatment group , 69 cases were collected in control group. The treatment group were given lactobacillus element capsule （Aopingshuan） every day, and continued for 10 days of vaginal medication at every menstruation, and continuous use of 4-6 menstrual cycles; Control group were given only follow-up. Results After 4 months of treatment, the reversal rate of CIN I at control group and treatment group was 20.64% and 29.58% respectively; After 6 months of treatment, the reversal rate of CIN I at control group and treatment group was 33.33% and 47.06% respectively; After 12 months of treatment, tthe reversal rate of CIN I at control group and , treatment group was 38.33% and 56.92% respectively;After 24 monuths of treatment, the reversal rate of GIN I at control group and treatment group was 51.85% and 70.00% respectively; Revesal rates of CIN I at 12 months and 24 mouths in treatment group were significantly higher than those in control group, P〈0.05. After treatment for 4 mouths, HR-HPV negative rate at control group and treatment group was 23.18% and 39.43% respectively;After 6 months, HR-HPV negative rate at both groups increased to 30.30% and 51.47% ;After 12 months, HR-HPV negative rate at both groups were 50.00% and 67.69% ; After treatment for 24 months, HR-HPV negative rate at control group and treatment group was 66.67% and 83.33% respectively;HR-HPV negative rates at

关 键 词：HR-HPv感染 宫颈上皮内瘤变I级 阴道用乳杆菌胶囊. 

分 类 号：R373.3[医药卫生—病原生物学]